is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to or fax to (405) 239-2112. 

Current Cases

CorMedix, Inc. [NYSE MKT: CRMD]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against CorMedix, Inc.


Oklahoma City, OK (July 9, 2015) – On July 7, 2015, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against CorMedix, Inc. (NYSE MKT: CRMD).  The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is March 12, 2011 through June 29, 2015.  More specifically, this litigation was filed because defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s announcements regarding its partnership discussions and imminent Phase 3 trials for its sole product, Neutrolin, were materially false and misleading;  (2) clinical studies touted by the Company were misleading and overstated  Neutrolin’s effectiveness when in fact Neutrolin offers no benefit compared to current industry protocols; (3) the Company overstated the cost effectiveness of Neutrolin compared to currently established medical protocols; (4) the Company’s market claims for Neutrolin were overstated; (5) the Company stock achieved an unsustainable valuation by using paid stock promoters, yet failed to disclose the use of such promoters in its regulatory filings pursuant to Section 17(b) of the Securities Act of 1933; (6) the Company insiders enriched themselves at the expense of shareholders by selling stock at inflated prices; and (7) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.


On June 29, 2015, an article by The Pump Stopper published on Seeking Alpha alleged that: 1) personnel involved in the formation of CorMedix had faced prior accusations of fraud; 2) Neutrolin’s performance in clinical trials was vastly overstated; and 3) the Company had engaged stock promoters in order to inflate the Company’s share price.  As a result of this news, the Company’s shares declined to close at $4.05 on June 29, 2015.


Plaintiff seeks to recover damages on behalf of all CorMedix, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above.  You may move the Court no later than Friday, September 4, 2015 to serve as a lead plaintiff for the entire Class.  However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification.  Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN:  Robin.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.